The U.S. Food and Drug Administration has approved Farydak (panobinostat) for the treatment of...
It’s financial reporting season and the pharmaceutical industry is no exception. This week...
Array BioPharma today announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.
Novartis announced that the FDA has approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
A panel of Food and Drug Administration experts ruled that the Novartis' version of Neupogen is highly similar to Amgen's original blockbuster biotech drug, which is used to boost blood cells that help cancer patients fight off infections.
Just over a week after saying it would sell its heartworm treatment for dogs at the request of federal regulators, Eli Lilly announced that it has completed its $5.4 billion acquisition of the animal health division belonging to Switzerland's Norvartis.
Acromegaly is a rare, debilitating endocrine disorder caused by the excess production of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). In the majority of cases, the disease is caused by a non-cancerous tumor on the pituitary gland.
Europe's drug regulator says there is no proof that a flu vaccine for the elderly was linked to side effects, including deaths in Italy. Last week, Italy pulled two batches of Fluad, made by Switzerland's Novartis AG, after reports that people died after getting immunized.
Novartis AG has posted a 45 percent rise in net profit in the third quarter, boosted by strong sales of new products such as Gilenya for multiple sclerosis and the leukemia drug Tasigna. The Basel, Switzerland-based company's reported quarterly net profit was $3.24B
CSL Limited today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the FDA voted 7 to 0 to support the approval of AIN457, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and Eli Lilly and Company in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis.
The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly. The 28-nation bloc's executive Commission said Friday the sale won't hinder competition because the merged firm will continue to face a number of strong competitors.
The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.
Merus Labs International has acquired from Novartis AG, in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom® (acenocoumarol).
Ophthotech Achieves $50M Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®September 8, 2014 8:07 am | News | Comments
Ophthotech Corporation today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD).
Five years after Congress passed a law allowing biosimilars, for the first time the FDA has accepted an application to sell a similar, but not identical, version of a biologic drug.
Novartis AG says its second-quarter profit rose 3 percent from a year earlier, reflecting solid growth and an increased focus on core products. The Basel-based company reports that profit during the April-June quarter rose to $3.28 billion, up from $3.18 billion in the same quarter of 2013.
Some things just seem to naturally go together – peanut butter and chocolate is one of those combinations – especially in the form of peanut butter cups. Bacon and eggs is another, as is peanut butter and jelly, pizza and beer and numerous other tasty combinations.
The drugmaker said its Alcon eye care division will license Google technology and work with a team from Google to develop a lens that uses microchips and miniaturized electronics.
Incyte Corporation announced today that it has earned a $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis.
Novartis announced that the FDA has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).
Tokyo prosecutors arrested a former employee of Novartis Pharma K.K. on Wednesday on a charge of manipulating clinical study data leading to exaggerated claims in advertising for one of the firm's drugs.
Italy's health ministry is seeking 1.2 billion euros ($1.63 billion) in damages from Swiss pharmaceutical giants Novartis and Roche after an anti-trust court ruled the two companies colluded to prevent the distribution of an eye medication.
According to a new report published by Transparency Market Research, "Meningococcal Vaccines Market - Global Industry Analysis 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.
The FDA has granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells.
The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.
- Page 1